Cardiotoxicity
Drug testing on cardiac action potential comes as a part of the cardiac safety evaluation to understand the prolongation of the QT interval on the electrocardiogram showing exactly the blockage occurring in the hERG channel. Stellixir Biotech has been providing automated electrophysiology tests. We have continued to provide expertise in binding Q Patch HT automated patch clamp and manual patch clamp assays. We have efficient, reliable, and cost-effective packages that help you predict cardiac risk earlier in your study and have quick turnaround times to check on your compounds that happen to have a cardiac liability.
In Vitro Assays Conducted by Stellixir Biotech
- functional mitochondrial toxicity (Seahorse)
- hERG safety screening using Invitrogen’s Predictor™ hERG fluorescence polarization assay kit
- 3D microtissue-based cardiotoxicity assay using human iPSC – CM (cardiomyocytes) spheroid cultures
Panel Name
The Comprehensive in vitro Proarrhythmia Assay (CiPA) Core Panel (3 Concentrations)
Key Features
Tier1 CiPA core panels include three cardiac ion channel targets (hERG, hNav1.5 peak, and hCav1.2) most commonly profiled beyond hERG for early cardiac risk assessment and mitigation. These panels are a logical first step for cardiac proarrhythmic risk prediction. Our expert electrophysiologists fully validate each assay to optimize assay performance and minimize the current rundown. Stellixir Biotech (with time-matched vehicle control and reference compound results included in each report) delivers reliable pharmacological test results.
The Comprehensive in vitro Proarrhythmia Assay (CiPA) Core Panel (5 Concentrations)
Panel Name
The Comprehensive in vitro Proarrhythmia Assay (CiPA) Panel (3 Concentrations)
Key Features
Tier2 CiPA panels include all seven cardiac ion channels as primary determinants of the ventricular action potential (Figure 2) recommended by the CiPA consortium. Our CiPA panels enable comprehensive mechanistic understanding to predict proarrhythmic risk for key candidate selection to progress into first-in-human trials. Our CiPA assays provide Giga ohm seal data quality with validated reference pharmacology that correlates well with gold-standard manual patch clamp assays. Stellixir Biotech is using protocols and technology-compliant tools that adhere to future regulatory guidelines offered on the industry's most adapted automated patch clamp technology Q Patch™ HT.
The Comprehensive in vitro Proarrhythmia Assay (CiPA) Panel (5 Concentrations)
Human iPSC-derived cardiomyocytes FLIPR Penta assays
Assay Name
Human iPSC-derived cardiomyocytes FLIPR Penta assay (4 Concentrations)
Key Features
Robust reference pharmacology data on fully validated markers with strong translational values
Affordable, precise, and high throughput assay for cardiac liability assessment in intact, beating human ventricular-like stem cells, a good first phase screening method